Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ((177)Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

LESSONS LEARNED: Hyperfractionation of lutetium‐177 ((177)Lu)‐J591 for patients with metastatic castration‐resistant prostate cancer did not appear to have any additional advantage over the single dose (177)Lu‐J591 or fractionated two‐dose (177)Lu‐J591 therapy. Definite conclusions were challenging...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Niaz, Muhammad Junaid, Batra, Jaspreet S., Walsh, Ryan D., Ramirez‐Fort, Marigdalia K., Vallabhajosula, Shankar, Jhanwar, Yuliya S., Molina, Ana M., Nanus, David M., Osborne, Joseph R., Bander, Neil H., Tagawa, Scott T.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288642/
https://ncbi.nlm.nih.gov/pubmed/31999003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados